Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 11, 2017, Pages 2125-2137

  Song, Y ^a   Wang, Z ^a   Perlstein, I ^a   Wang, J ^a   LaCreta, F ^a   Frost, R J A ^a   Frost, C ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

anticoagulants; apixaban; healthy volunteers; pharmacokinetics; prothrombin complex concentrates

Indexed keywords

ANTITHROMBIN III; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; CITRATE TRISODIUM; HEPARIN; HYDROCHLORIC ACID; PLACEBO; PROTEIN C; PROTEIN S; PROTHROMBIN; PROTHROMBIN COMPLEX; SODIUM CHLORIDE; SODIUM HYDROXIDE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; COAGULATING AGENT; PROTHROMBIN COMPLEX CONCENTRATES; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THROMBIN;

ABDOMINAL PAIN; ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; STEADY STATE; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD CLOTTING TEST; DRUG EFFECT; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; COAGULANTS; CROSS-OVER STUDIES; FACTOR XA INHIBITORS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; THROMBIN; YOUNG ADULT;

EID: 85032788752     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13815     Document Type: Article

References (46)

1. Bristol-Myers Squibb. Coumadin prescribing information. http://packageinserts.bms.com/pi/pi_coumadin.pdf. Accessed 3 March 2015.
2. Goldstein JN, Refaai MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385: 2077–87.
3. Boehringer Ingelheim. Pradaxa (dabigatran) PI. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf. Accessed 7 July 2016.
4. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511–20.
5. Ansell JE. Reversing the effect of oral anticoagulant drugs: established and newer options. Am J Cardiovasc Drugs 2016; 16: 163–70.
6. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL, Siegal DM, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131–41.
7. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413–24.
8. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014; 371: 2141–2.
9. Lam WW, Reyes MA, Seger JJ. Plasma exchange for urgent apixaban reversal in a case of hemorrhagic tamponade after pacemaker implantation. Tex Heart Inst J 2015; 42: 377–80.
10. Kamboj J, Kottalgi M, Cirra VR, Shah N, Kamboj R. Direct thrombin inhibitors: a case indicating benefit from ‘plasmapheresis’ in toxicity: a call for establishing ‘guidelines’ in overdose and to find an ‘antidote’! Am J Ther 2012; 19: e182–5.
11. Babilonia K, Trujillo T. The role of prothrombin complex concentrates in reversal of target specific anticoagulants. Thromb J 2014; 12: 8.
12. ® (Prothrombin Complex Concentrate [Human]) Prescribing information. http://labeling.cslbehring.com/PI/US/Kcentra/EN/Kcentra-Prescribing-Information.pdf. Accessed 13 July 2016.
13. Escolar G, Fernandez-Gallego V, Arellano-Rodrigo E, Roquer J, Reverter JC, Sanz VV, Molina P, Lopez-Vilchez I, Diaz-Ricart M, Galan AM. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS ONE 2013; 8: e78696.
14. Herzog E, Kaspereit F, Krege W, Mueller-Cohrs J, Doerr B, Niebl P, Dickneite G. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage. J Thromb Haemost 2015; 13: 2220–6.
15. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, Godier A. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013; 168: 4228–33.
16. Cheung YW, Barco S, Hutten BA, Meijers JC, Middeldorp S, Coppens M. In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers. J Thromb Haemost 2015; 13: 1799–805.
17. Nagalla S, Thomson L, Oppong Y, Bachman B, Chervoneva I, Kraft WK. Reversibility of apixaban anticoagulation with a four-factor prothrombin complex concentrate in healthy volunteers. Clin Transl Sci 2016; 9: 176–80.
18. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4–15.
19. Hemker HC, Al Dieri R, de Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic–thrombotic system. Thromb Haemost 2006; 96: 553–61.
20. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 2010; 104: 1263–71.
21. Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH, Song Y, Aubry AF, Arnold ME. LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis 2014; 6: 2071–82.
22. Costin J, Ansell J, Laulicht B, Bakhru S, Steiner S. Reversal agents in development for the new oral anticoagulants. Postgrad Med 2014; 126: 19–24.
23. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012; 108: 217–24.
24. Perzborn E, Heitmeier S, Laux V, Buchmuller A. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thromb Res 2014; 133: 671–81.
25. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124: 1573–9.
26. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost 2014; 12: 1428–36.
27. Zahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, Lomeli B, Feussner A, Feng W, He L, Grosso MA, Lanz HJ, Antman EM. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015; 131: 82–90.
28. Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for rivaroxaban. J Thromb Haemost 2013; 11: 1111–18.
29. Sadeghi N, Kahn D, Jeske W, Hoppensteadt D, Fareed J. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication. Clin Appl Thromb Hemost 2013; 19: 589–99.
30. CSL Behring GmbH. Beriplex P/N 250 IU. Summary of product characteristics. http://www.medicines.org.uk/emc/medicine/21147. Accessed 13 July 2016.
31. Sanquin. Cofact Summary of product characteristics. 27/02/2011. http://www.sanquin.nl/repository/documenten/en/prod-en-dienst/plasmaproducten/Cofact/Summary_of_product_characteristics.pdf. Accessed 4 May 2016.
32. Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol 2013; 5: 177–84.
33. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, LaCreta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013; 76: 776–86.
34. Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, LaCreta F, Hiraoka M. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther 2014; 52: 564–73.
35. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013; 110: 283–94.
36. Elg M, Carlsson S, Gustafsson D. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb Res 2001; 101: 145–57.
37. Scharbert G, Thaler U, Weilnbock C, Wetzel L, Kozek-Langenecker S. Heparin-induced effects of prothrombin complex concentrates in thromboelastometry. Wien Klin Wochenschr 2012; 124: 320–5.
38. Hansson KM, Bjorkqvist J, Deinum J. Addition of prothrombin to plasma can result in a paradoxical increase in activated partial thromboplastin time. Blood Coagul Fibrinolysis 2014; 25: 851–5.
39. Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd RA, LaCreta F. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clin Pharmacol 2014; 6: 179–87.
40. Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. http://packageinserts.bms.com/pi/pi_eliquis.pdf. Accessed 25 February 2016.
41. Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, Frost C. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14: 147–54.
42. Beynon C, Potzy A, Unterberg AW, Sakowitz OW. Emergency neurosurgical care in patients treated with apixaban: report of 2 cases. Am J Emerg Med 2015; 33: 858.e5–858.e7.
43. Durie R, Kohute M, Fernandez C, Knight M. Prothrombin complex concentrate for the management of severe traumatic bleeding in a patient anticoagulated with apixaban. J Clin Pharm Ther 2016; 41: 92–3.
44. Kauffmann S, Chabanne R, Coste A, Longeras F, Sinegre T, Schmidt J, Samama CM, Constantin JM, Lebreton A. Favorable outcome of rivaroxaban-associated intracerebral hemorrhage reversed by 4-factor prothrombin complex concentrate: impact on thrombin generation. A A Case Rep 2015; 4: 151–4.
45. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015; 17: 1467–507.
46. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer EA, Ozier Y, Riddez L, Schultz A, Vincent JL, Spahn DR. The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition. Crit Care 2016; 20: 100.